B-RAF (V600E) inhibitors (e.g. vemurafenib, dabrafenib) [11] were the first targeted therapy in melanoma and have been associated with significant improvements in both progression-free survival and overall survival compared with chemotherapy in patients with B-RAF mutated metastatic melanoma [12]-[16]. This evidence concerns the gene BRAF and melanoma.